5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease

Agents and Actions

Volumn 36, Issue 1 Supplement, 1992, Pages

  Rask Madsen, J ^a   Bukhave, K ^b   Laursen, L S ^c   Lauritsen, K ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ARACHIDONIC ACID; CORTICOSTEROID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MESALAZINE; SALAZOSULFAPYRIDINE; 3 (3,5 DI TERT BUTYL 4 HYDROXYANILINO)BENZOIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ALPHA TOCOPHEROL; ARACHIDONATE 5 LIPOXYGENASE; ENZYME INHIBITOR; LEUKOTRIENE B4; N (4 BENZYLOXYBENZYL)ACETOHYDROXAMIC ACID; N [3 (5,6,7,8 TETRAHYDRO 2 NAPHTHYL)ALLYL]ACETOHYDROXAMIC ACID; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN E2; ZILEUTON;

ANIMAL; CLINICAL TRIAL; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENTERITIS; HUMAN; INTESTINE MUCOSA; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REVIEW; ANIMAL MODEL; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HISTOLOGY; INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; AMINOSALICYLIC ACIDS; ANIMAL; ARACHIDONIC ACID; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; HUMAN; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MESALAMINE; SULFASALAZINE;

EID: 0026551228     PISSN: 00654299     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/BF01991022     Document Type: Article

References (84)

1. Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: An integrated approach to inflammation of human skin
2. Psoriasis
3. Eicosanoids and rheumatology: Inflammatory and vascular aspects
4. Leukotrienes: Their formation and roles as inflammatory mediators
5. Leucocytes in asthma
6. Eicosanoids, epithelium and airway reactivity
7. Toward the formulation of a theory of asthma
8. Effect of calcium ionophore A 23187 and of leukotrienes B4and C4on the adherence of mononuclear leucocytes in multiple sclerosis
9. Arachidonic acid metabolites in inflammatory bowel disease
10. Role of eicosanoids in human and experimental colitis
11. Generation and recognition of leukotriene mediators of hypersensitivity and inflammation
12. Inflammatory intermediaries in inflammatory bowel disease
13. Eicosanoids in inflammatory bowel disease — Physiology and pathology
14. Introduction of a nomenclature: Leukotrienes
15. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes
16. Leukotriene B: A potential mediator of inflammation
17. Effect of various lipoxygenase metabolites of arachidonic acid on degranulation of polymorphonuclear leukocytes
18. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity
19. The role of arachidonic acid oxygenation products in pain and inflammation
20. Slow-reacting substances of anaphylaxis: Identification of leukotrienes C-1 and D from human and rat sources
21. Slow-reacting substances, leukotrienes C4and D4, increase the release of mucus from human airways in vitro
22. Studies of prostaglandins and sulfasalazine
23. Prostaglandin synthesis inhibitors in ulcerative colitis: Flurbiprofen compared with conventional treatment
24. Inhibitors of 5-lipoxygenase and leukotriene formation in inflammatory bowel disease
25. Biochemical studies on mammalian lipoxygenases
26. Role of the 15-lipoxygenase in the immune system
27. Endothelial cell leukotriene C4synthesis results from intercellular transfer of leukotriene A4synthesized by polymorphonuclear leukocytes
28. Identification and isolation of a membrane protein necessary for leukotriene production
29. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes
30. Characterization of the human 5-lipoxygenase gene
31. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
32. Alterations of the immune system in ulcerative colitis and Crohn's disease
33. Enhanced synthesis of leukotriene B4by colonic mucosa in inflammatory bowel disease
34. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: Inhibition by sulfasalazine and 5-aminosalicylic acid
35. Biosynthesis of lipoxygenase and cyclo-oxygenase products from14C-arachidonic acid by human colonic mucosa
36. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2and leukotriene B4levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis
37. Drug treatment and formation of eicosanoids in patients with inflammatory bowel disease
38. Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4
39. Eicosanoids as bioregulators in clinical medicine
40. The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs)
41. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis and Clostridium difficile colitis
42. Role of sulfidopeptide leukotrienes in inflammatory bowel disease
43. Effect of therapy on eicosanoid formation in inflammatory bowel disease
44. The role of eicosanoids in inflammatory bowel disease
45. Eicosanoids and inflammatory bowel disease: Regulation and prospects for therapy
46. Macrocortin: A polypeptide causing the anti-phospholipase effect of glucocorticoids
47. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis
48. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: A possible mode of action in ulcerative colitis
49. Soybean lipoxygenase inhibition: Studies with sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine
50. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils
51. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid
52. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products
53. Fish oil modified neutrophil (PMN) function in ulcerative colitis
54. Effects of long-term application of fish oil in patients with Crohn's disease (CD)
55. Reduced leukotriene (LT) B4and increased LTB5synthesis in ulcerative colitis (UC) with fish oil
56. Therapeutic potential of fish oil in the treatment of ulcerative colitis
57. Treatment of ulcerative colitis with fish oil n-3-ω-fatty acid: An open trial
58. Maintenance of remission in ulcerative colitis using fish oil omega-3 fatty acid
59. Controlled double blind cross over study of eicosapentanoid acid (EPA) in chronic ulcerative colitis
60. A trial of fish oil supplemented diet in ulcerative colitis
61. Does vitamin E supplementation modulate in vivo arachidonate metabolism in human inflammation?
62. Fish oil in ulcerative colitis: Final results of a controlled clinical trial
63. 2,3-dihydro-5-benzofuranols as antioxidant-based inhibitors of leukotriene biosynthesis
64. Eicosanoids and their role in the pathogenesis of diarrhoeal diseases
65. Orally active hydroxamic acid inhibitors of leukotriene biosynthesis
66. Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis
67. Animal models of inflammatory bowel disease
68. Inhibition of rectal biopsy leukotriene (LT) synthesis by the 5-lipoxygenase (5LO) inhibitor BWA4C in ulcerative colitis (UC)
69. In vitro leucotriene B4production in ulcerative colitis: Effects of three potentially efficacious new agents (SC45662, SC41930 & misoprostol)
70. Selective 5-lipoxygenase inhibition in ulcerative colitis
71. Experimental use of a 5-lipoxygenase inhibitor (Abbott-64077) in human ulcerative colitis (UC)
72. Abbott-64077, a potent lipoxygenase inhibitor in the treatment of ulcerative colitis
73. 5-Lipoxygenase inhibition in double-blind trial with zieleciton: How much is sufficient in active ulcerative colitis?
74. Leukotriene receptor antagonists as potential therapeutic agents
75. Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes
76. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases
77. Perspectives on additional areas for research in leukotrienes
78. Leukotriene receptors and signal transduction mechanism
79. Selective inhibitor of slow reacting substance of anaphylaxis
80. Receptor-specific mechanisms for the responses of human leukocytes to leukotrienes
81. Regulation of the receptor system for leukotriene B4on human neutrophils
82. Novel leukotriene antagonists: Structure activity of analogs of LTD4. Replacement of the l-carboxylic group by a methyl group (“methyl principle”) results in leukotriene antagonists and phospholipase inhibitors
83. CGP 35949: A potent leukotriene antagonist and inhibitor of phospholipase. Biological profile
84. Wy-45.911: A novel leukotriene antagonist with lipoxygenase inhibitory activity